Emmaus Life Sciences Q2 revenue soars on licensing deal
EMMA•Reported quarterly results and outlook
The company did not provide specific guidance for the current or future periods in the press release.
Key details
| Metric | Actual |
|---|---|
| Q2 Net Revenues | $6.32 mln |
| Q2 EPS | $0.02 |
| Q2 Net Income | $1.34 mln |
| Q2 Gross Profit | $5.97 mln |
| Q2 Income from Operations | $3.79 mln |
| Q2 Operating Expenses | $2.18 mln |
Operating expenses fall after sales force transfer
Emmaus said operating costs declined following the transfer of its sales force to NeoImmuneTech.
The company posted net income for the quarter, reversing a loss from the prior-year period.
Q2 revenue and profit jump on NeoImmuneTech licensing deal
Emmaus Life Sciences said second-quarter revenue rose 124% year over year, driven by its NIT license agreement.
The company said the growth came from an upfront payment and royalties from the NeoImmuneTech license agreement.
